AVA7367: Lead Development Compound

​

• A novel, proprietary, potent, orally available small molecule dual antagonist of the a4b1 and a4b7 integrins

• Pharmacological profile and IND enabling studies support development for Inflammatory Bowel Disease (IBD) and other Inflammatory conditions.

• Licensing/acquisition inquires welcome